BioSenic Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	no data
Board average tenure	2.1yrs

Recent management updates

Recent updates

CEO

BioSenic has no CEO, or we have no data on them.

Board Members

Name	Position	Tenure	Compensation	Ownership
Bernard Malissen	Member of Scientific Advisory Board	no data	no data	no data
Jean-François Bach	Member of Scientific Advisory Board	no data	no data	no data
Yves Sagot	Independent Director	1.8yrs	no data	no data
Alain Fischer	Member of Scientific Advisory Board	no data	no data	no data
Jean-Luc Vandebroek	Non-Executive Director	2.1yrs	no data	no data
Jean-François Rax	Non-Executive Director	2.1yrs	no data	no data
Jules Hoffmann	Chairman of Scientific Advisory Board	no data	no data	no data
Carlo Chizzolini	Member of Scientific Advisory Board	no data	no data	no data
Frédéric Houssiau	Member of Scientific Advisory Board	no data	no data	no data
Revital Rattenbach	Independent Director	2.1yrs	no data	no data
Jean Stephenne	Independent Director	2.1yrs	no data	no data

2.1yrs

Average Tenure

Experienced Board: BT1's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.

BioSenic Management

Management criteria checks 0/4

Key information

Recent management updates

BioSenic S.A. Announces Executive Changes

Véronique Pomi-Schneiter Step Down as BioSenic's Deputy CEO

Biosenic S.A. and Its Subsidiary Medsenic SAS Announces the Promotion of Carole Nicco to Chief Operating Officer

BioSenic S.A. Appoints Yves Sagot as Independent Director

BioSenic Appoints Dr. Carole Nicco as Chief Scientific Officer

BioSenic S.A. Appoints Michel Wurm as Interim Chief Medical Officer

Recent updates

BioSenic S.A. Announces Executive Changes

Véronique Pomi-Schneiter Step Down as BioSenic's Deputy CEO

Medsenic, Subsidiary of Biosenic Receives the Intention to Grant Key European Patent from European Patent Office

Biosenic Releases New In-Depth Analysis of Its Positive Phase 2 Clinical Data for Optimal Administration Scheme for Its Next Late-Stage Trial of Arsenic Trioxide (Ato) Targeting Cgvhd

New major risk - Shareholder dilution

BioSenic S.A. to Report Fiscal Year 2023 Results on Jun 06, 2024

Biosenic S.A. Releases Details of Optimized Administration Approach Ahead of Planned Phase 3 Trial of OATO for Chronic Graft-Versus-Host Disease

BioSenic S.A. Patent Granted in Canada for Broader Protection of ATO Therapeutic Platform

BioSenic Presents New Phase 3 Data on JTA-004 to Treat Severe Osteoarthritis Pain at the 2024 OARSI World Congress

BioSenic Files for Additional Patent Protection Following New Clinical Evidence of Efficacy for JTA-004 in OA

Biosenic S.A. and Its Subsidiary Medsenic SAS Announces the Promotion of Carole Nicco to Chief Operating Officer

New major risk - Market cap size

BioSenic S.A. Performs Further Analysis of Its Phase 2 Clinical Trial Data, Leading to an Optimal Administration Scheme for Its Next Late-Stage Trial of Arsenic Trioxide in cGvHD

BioSenic Publishes New Evidence of Beneficial Effects of Arsenic Treatment Supporting Clinical Trial for Systemic Sclerosis

New major risk - Market cap size

BioSenic S.A. Puts Phase IIb Allob Trial on Hold

BioSenic S.A. Appoints Yves Sagot as Independent Director

BioSenic Appoints Dr. Carole Nicco as Chief Scientific Officer

BioSenic S.A. Appoints Michel Wurm as Interim Chief Medical Officer

Less than half of directors are independent

BioSenic SA provides update on its autoimmune disease platform based on ATO (arsenic trioxide)

Less than half of directors are independent

CEO

Board Members

Average Tenure